Kymera Therapeutics, Inc. Common Stock (KYMR) Stock
NASDAQ · KYMR
Key stats
- Market cap
- $11.51B
- Price / Earnings ratio
- -33.4x
- EPS (TTM)
- -$3.63
- Volume
- Loading
- 52-week high
- $142.92
- 52-week low
- $60.25
Source: third-party data provider, as of November 13, 2026
Compare with KYMR
Recent news

MarketBeat
Kymera Therapeutics Q3 Earnings Call Highlights
PositiveKYMROctober 29, 2026
MarketBeatPositive
Kymera Therapeutics Q3 Earnings Call Highlights
KYMR

Zacks Investment Research
Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth?
NeutralKYMROctober 19, 2026
Zacks Investment ResearchNeutral
Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth?
KYMR

Stocktwits
Cathie Wood-Led Ark Invest Sells AMD, SPCX, GOOG Stocks — But Loads Up On CMPS, NTLA, CRSP And Other Healthcare Firms
KYMROctober 10, 2026
Stocktwits
Cathie Wood-Led Ark Invest Sells AMD, SPCX, GOOG Stocks — But Loads Up On CMPS, NTLA, CRSP And Other Healthcare Firms
KYMR

Zacks Investment Research
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
PositiveKYMRSeptember 4, 2026
Zacks Investment ResearchPositive
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
KYMR
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 64.48
- MACD 12/26/9
- 6.25
- EMA 9 of MACD
- 4.56
- MACD histogram
- 1.69
- SMA 50
- $116.75
- Price above SMA 50
- EMA 50
- $118.57
- Price above EMA 50
- SMA 200
- $98.90
- Price above SMA 200
- EMA 200
- $99.75
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 12 analyst ratings
Strong Sell0
Sell0
Hold1
Buy11
Strong Buy0
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Revenue
Net income
Net margin %
2021
2022
2023
2024
2025
94M62M31M0
Debt & Balance Sheet
Total assets
Total liabilities
2021
2022
2023
2024
2025
2B1B690M0
Revenue to Profit
2025$39.2M
Revenue$0.0
Cost of revenue$39.2M
Gross profit$0.0
Operating expenses$-311.4M
Net incomeEarnings
No data available
Source: third-party data provider
Latest news

MarketBeat
Kymera Therapeutics Q3 Earnings Call Highlights
PositiveKYMROctober 29, 2026
MarketBeatPositive
Kymera Therapeutics Q3 Earnings Call Highlights
KYMR

Zacks Investment Research
Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth?
NeutralKYMROctober 19, 2026
Zacks Investment ResearchNeutral
Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth?
KYMR

Stocktwits
Cathie Wood-Led Ark Invest Sells AMD, SPCX, GOOG Stocks — But Loads Up On CMPS, NTLA, CRSP And Other Healthcare Firms
KYMROctober 10, 2026
Stocktwits
Cathie Wood-Led Ark Invest Sells AMD, SPCX, GOOG Stocks — But Loads Up On CMPS, NTLA, CRSP And Other Healthcare Firms
KYMR

Zacks Investment Research
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
PositiveKYMRSeptember 4, 2026
Zacks Investment ResearchPositive
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
KYMR

Zacks Investment Research
Can KT-621 Mark a Turning Point for Kymera Therapeutics?
PositiveKYMRSeptember 3, 2026
Zacks Investment ResearchPositive
Can KT-621 Mark a Turning Point for Kymera Therapeutics?
KYMR

Zacks Investment Research
KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments
KYMRAugust 6, 2026
Zacks Investment Research
KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments
KYMR

MarketBeat
Kymera Therapeutics Q2 Earnings Call Highlights
KYMRAugust 5, 2026
MarketBeat
Kymera Therapeutics Q2 Earnings Call Highlights
KYMR

Zacks Investment Research
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates
KYMRAugust 5, 2026
Zacks Investment Research
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates
KYMR

Zacks Investment Research
Is Kymera Therapeutics Poised for a Breakthrough With KT-621?
KYMRJuly 24, 2026
Zacks Investment Research
Is Kymera Therapeutics Poised for a Breakthrough With KT-621?
KYMR

The Motley Fool
Kymera's CEO Sold $6 Million in Stock After a 170% Run
KYMRJuly 12, 2026
The Motley Fool
Kymera's CEO Sold $6 Million in Stock After a 170% Run
KYMR
News tone: automated (AI) classification of the article's content, not a price prediction.
About Kymera Therapeutics, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees273
CEODr. Nello Mainolfi M.D., Ph.D.
IPO DateAug 21, 2020
HeadquartersWatertown, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Nello Mainolfi M.D., Ph.D. | Co-Founder, President, CEO & Director | 1979 |
| Mr. Bruce N. Jacobs CFA | Chief Financial Officer | — |
| Mr. Brian R. Adams J.D. | Chief Legal Officer & Corporate Secretary | 1974 |
| Dr. Jared A. Gollob M.D. | Advisor | 1965 |
| Mr. Noah Goodman M.B.A. | Chief Business Officer | 1987 |
| Ms. Justine E. Koenigsberg | Vice President of Investor Relations | — |
| Dr. Neil Graham M.D., M.P.H., MBBS | Chief Development Officer | 1959 |
| Mr. Brian Albarran M.B.A., Ph.D. | SVP of Corporate Strategy | — |
| Dr. Juliet Williams B.A Ph.D. | Head of Research |